[{"data":1,"prerenderedAt":259},["ShallowReactive",2],{"drug-ertapenem":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":126,"warnings":136,"renal":144,"monitoring":156,"interactions":157,"review":165,"examples":168,"atc":193,"iran":195,"usApproval":202,"links":208,"populations":225},"ertapenem",1,{"fa":7,"en":8},"ارتاپنم","Ertapenem","anti-infectives",{"fa":11,"en":12},"کارباپنم","Carbapenem",[14],{"name":15,"market":16},"Invanz","US",[18,19,7],"invanz","اینوانز",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"vial-1g","powder-for-injection","iv","1 g vial (IV or IM)",{"amount":27,"unit":28,"perUnit":29},1000,"mg","vial",[16],[32],{"source":33,"section":34},"fda-ertapenem","3",[36,63,84,97,112],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"durationDays":51,"notes":54},"dfi","diabetic-foot-infection",{"fa":40,"en":41},"عفونت پای دیابتی بدون استئومیلیت — ۱۳ سال به بالا ۱ g یک بار در روز، ۷ تا ۱۴ روز","Diabetic foot infection without osteomyelitis — ≥13 y 1 g once daily, 7–14 days",{"minAge":43},{"value":44,"unit":45},13,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"2.2, Table 1",{"min":52,"max":53},7,14,[55],{"text":56,"refs":59},{"fa":57,"en":58},"در پای دیابتی با استئومیلیت همزمان بررسی نشده است. انفوزیون ۳۰ دقیقه‌ای؛ با دکستروز رقیق نشود.","Not studied in diabetic foot infection with concomitant osteomyelitis. Infuse over 30 min; no dextrose diluents.",[60,61],{"source":33,"section":50},{"source":33,"section":62},"2.1",{"id":64,"disease":38,"label":65,"population":68,"type":73,"unit":28,"dose":74,"refs":77,"limits":79,"durationDays":83},"dfi-child",{"fa":66,"en":67},"عفونت پوست شامل پای دیابتی — کودک ۳ ماه تا ۱۲ سال: ۱۵ mg\u002Fkg دو بار در روز (حداکثر ۱ g\u002Fروز)","Skin infection incl. diabetic foot — child 3 months–12 y: 15 mg\u002Fkg twice daily (max 1 g\u002Fday)",{"minAge":69,"maxAge":72},{"value":70,"unit":71},3,"month",{"value":44,"unit":45},"weightBased",{"perKgPerDose":75,"intervalHours":76},15,12,[78],{"source":33,"section":50},{"maxPerDay":27,"refs":80},[81],{"source":33,"section":82},"2.2",{"min":52,"max":53},{"id":85,"disease":86,"label":87,"population":90,"type":46,"unit":28,"dose":92,"refs":93,"durationDays":95},"iai","intra-abdominal-infection",{"fa":88,"en":89},"عفونت عارضه‌دار داخل شکم — ۱۳ سال به بالا ۱ g یک بار در روز، ۵ تا ۱۴ روز","Complicated intra-abdominal infection — ≥13 y 1 g once daily, 5–14 days",{"minAge":91},{"value":44,"unit":45},{"perDose":27,"dosesPerDay":5},[94],{"source":33,"section":50},{"min":96,"max":53},5,{"id":98,"disease":86,"label":99,"population":102,"type":73,"unit":28,"dose":105,"refs":106,"limits":108,"durationDays":111},"iai-child",{"fa":100,"en":101},"عفونت داخل شکم — کودک ۳ ماه تا ۱۲ سال: ۱۵ mg\u002Fkg دو بار در روز (حداکثر ۱ g\u002Fروز)","Intra-abdominal infection — child 3 months–12 y: 15 mg\u002Fkg twice daily (max 1 g\u002Fday)",{"minAge":103,"maxAge":104},{"value":70,"unit":71},{"value":44,"unit":45},{"perKgPerDose":75,"intervalHours":76},[107],{"source":33,"section":50},{"maxPerDay":27,"refs":109},[110],{"source":33,"section":82},{"min":96,"max":53},{"id":113,"disease":114,"label":115,"population":118,"type":46,"unit":28,"dose":121,"refs":122,"durationDays":125},"proph","surgical-prophylaxis",{"fa":116,"en":117},"پیشگیری از عفونت پس از جراحی انتخابی کولورکتال — ۱ g وریدی یک ساعت پیش از برش","Prophylaxis for elective colorectal surgery — 1 g IV 1 h before incision",{"minAge":119},{"value":120,"unit":45},18,{"perDose":27,"dosesPerDay":5},[123],{"source":33,"section":124},"2.3",{"min":5,"max":5},[127],{"id":128,"severity":129,"text":130,"refs":133},"hyper","block",{"fa":131,"en":132},"حساسیت به اجزای فرآورده یا سایر کارباپنم‌ها؛ آنافیلاکسی با بتالاکتام‌ها. تزریق عضلانی (با لیدوکائین): حساسیت به بی‌حس‌کننده‌های آمیدی.","Hypersensitivity to any component or other carbapenems; anaphylaxis with beta-lactams. IM (lidocaine diluent): hypersensitivity to amide local anaesthetics.",[134],{"source":33,"section":135},"4",[137],{"text":138,"refs":141},{"fa":139,"en":140},"واکنش آلرژیک جدی؛ تشنج و عوارض CNS؛ اسهال C. difficile. با والپروات سطح آن کم و خطر تشنج بیشتر می‌شود.","Serious hypersensitivity; seizures and CNS effects; C. difficile diarrhoea. Lowers valproate levels with breakthrough seizure risk.",[142],{"source":33,"section":143},"5",[145],{"egfrBelow":146,"severity":147,"text":148,"refs":151},31,"warn",{"fa":149,"en":150},"ClCr ۳۰ و کمتر (و ESRD): ۵۰۰ mg روزانه. همودیالیز: اگر دوز ظرف ۶ ساعت پیش از دیالیز داده شد ۱۵۰ mg مکمل پس از دیالیز.","CrCl ≤30 (and ESRD): 500 mg daily. Haemodialysis: give 150 mg after dialysis if the daily dose was given within 6 h before.",[152,154],{"source":33,"section":153},"2.4",{"source":33,"section":155},"2.5",[],[158],{"with":159,"text":160,"refs":163},"valproate",{"fa":161,"en":162},"والپروات و دیوالپروکس: کاهش سطح والپروات و تشنج.","Valproic acid and divalproex: reduced valproate levels and seizures.",[164],{"source":33,"section":143},{"status":166,"reviewer":167,"date":167},"unverified",null,[169,174,181,186,189],{"regimen":37,"formulation":22,"input":170,"expect":173},{"ageYears":171,"weightKg":172},60,85,{"perDose":27,"dosesPerDay":5},{"regimen":64,"formulation":22,"input":175,"expect":178},{"ageYears":176,"weightKg":177},6,20,{"perDose":179,"dosesPerDay":180},300,2,{"regimen":85,"formulation":22,"input":182,"expect":185},{"ageYears":183,"weightKg":184},50,70,{"perDose":27,"dosesPerDay":5},{"regimen":98,"formulation":22,"input":187,"expect":188},{"ageYears":176,"weightKg":177},{"perDose":179,"dosesPerDay":180},{"regimen":113,"formulation":22,"input":190,"expect":192},{"ageYears":171,"weightKg":191},80,{"perDose":27},[194],"J01DH03",{"status":196,"refs":197},"not-found",[198],{"source":199,"section":200,"url":201},"darooyab-generic","G-389\u002FErtapenem","https:\u002F\u002Fwww.darooyab.ir\u002FG-389\u002FErtapenem",{"kind":203,"refs":204,"id":207},"ANDA",[205],{"source":33,"section":206},"SPL approval \u002F marketing category","ANDA207647",[209,212,216,220,223],{"kind":210,"url":211,"label":207},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=207647",{"kind":213,"url":214,"label":215},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5b050245-aa03-4e28-e063-6394a90aeabc","FDA Ertapenem",{"kind":217,"url":218,"label":219},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614001.html","Ertapenem Injection",{"kind":221,"url":222,"label":194},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01DH03",{"kind":224,"url":201,"label":8},"darooyab",{"pregnancy":226,"lactation":235,"pediatric":243,"geriatric":251},{"level":227,"text":228,"quote":231,"refs":232},"caution",{"fa":229,"en":230},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data from a small number of post-marketing cases with Ertapenem for injection use in pregnancy are insufficient to inform any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.",[233],{"source":33,"section":234},"8.1",{"level":227,"text":236,"quote":239,"refs":240},{"fa":237,"en":238},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Ertapenem is present in human milk (see Data ).",[241],{"source":33,"section":242},"8.2",{"level":227,"text":244,"quote":247,"refs":248},{"fa":245,"en":246},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of Ertapenem for injection in pediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled trials in adults, pharmacokinetic data in pediatric patients, and additional data from comparator-controlled trials in pediatric patients 3 months to 17 …",[249],{"source":33,"section":250},"8.4",{"level":227,"text":252,"quote":255,"refs":256},{"fa":253,"en":254},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.2) ].",[257],{"source":33,"section":258},"8.5",1792156177236]